Adeno-associated virus-based vectors in gene therapy

Jacov Tal

Research output: Contribution to journalReview articlepeer-review

55 Scopus citations


Adeno-associated virus (AAV) vectors were shown capable of high efficiency transduction of both dividing and nondividing cells and tissues. AAV-mediated transduction leads to stable, long-term transgene expression in the absence of apparent immune response. These properties and the broad host range of AAV vectors indicate that they constitute a powerful tool for gene therapy purposes. An additional potential benefit of AAV vectors is their ability to integrate site-specifically in the presence of Rep proteins which can be expressed transiently, thus limiting their suspected adverse effects. The major restrictions of AAV as vectors are their limited genetic capacity and strict packaging size constraint of less than 5 kb. Another difficulty is the labor-intensive and expensive procedure for the production and packaging of recombinant AAV vectors. The major benefits and drawbacks of AAV vectors and advances made in the past 3 years are discussed. (C) 2000 National Science Council, ROC and S. Karger AG, Basel.

Original languageEnglish
Pages (from-to)279-291
Number of pages13
JournalJournal of Biomedical Science
Issue number4
StatePublished - 1 Jan 2000


  • Adeno-associated virus
  • Gene expression
  • Gene transduction
  • Integration, site-specific

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Molecular Biology
  • Clinical Biochemistry
  • Cell Biology
  • Biochemistry, medical
  • Pharmacology (medical)


Dive into the research topics of 'Adeno-associated virus-based vectors in gene therapy'. Together they form a unique fingerprint.

Cite this